Skip to main content
. 2022 May 20;10(5):1187. doi: 10.3390/biomedicines10051187

Table 1.

Examples of Dtx–loaded delivery systems for anticancer therapy.

DDS Material Size [nm] EE [%] Drug Preparation Method Location Status Ref.
GNRs/liposomes DSPE-PEG2000, CHOL, SPC, HSPC, RLT, PEG 163.15 ± 1.83 98.45 ± 0.37 Dtx Film hydration Prostate In vitro-PC-3 cells
In vivo-mice		 [76]
Liposomes DSPE-PEG2000, CHOL, SPC, cetuximab 67.47 ± 4.32 99.95 Dtx Film hydration Prostate In vitro–PC-3, DU145 cells [77]
Liposomes DSPE-PEG2000, CHOL, SPC, transferrin 220.23 ± 3.95 37 ± 3.15 Dtx Film hydration Prostate In vitro–PC-3, PNT2 cells [79]
Dendrimers PAMAM n/d n/d Dtx/Ptx Covalent method Breast In vitro–SKBR-3 cells [86]
NPs PLGA, FA 227.6 ± 5.9 n/d Dtx Solvent-evaporation Breast In vitro–HeLa, MCF-7 cells
In vivo–mice 		[14]
NPs Au 18 n/d Dtx Chemical reduction Lung In vitro–H520 cells [98]
NPs GX1, PEG, DA, DGC 150.9 ± 3.5 52.7 ± 4.4 Dtx Dialysis Gastric In vitro–co-HUVEC
In vivo-mice		 [91]
NPs PCL, Pluronic F108 216 ± 3.4 86.0 ± 3.9 Dtx Nanoprecipitation Breast In vitro–BT-474 cells
In vivo–mice		 [92]
NPs Albumin, aptamer 62 ± 0.6 90.0 ± 0.7 Dtx Salting-out method Colon In vitro–CT26 cells
In vivo–mice		 [93]
SLNPs Span 80, Pluronic F127 128 ± 2.2 86.0 ± 2.4 Dtx N/d Breast In vitro–4T1 cells
In vivo–mice		 [82]
NPs Chondroitin sulphate, zein 157.8 ± 3.6 64.2 ± 1.9 Dtx Solvent displacement Prostate In vitro–PC-3 cells
In vivo-mice		 [99]
NPs fluorescein-labelled wheat germ agglutinin (fWGA)-conjugated disulfide cross-linked sodium alginate 289 17.8 Dtx N/d Colon In vitro–HT-29 cells [88]
Synthetic high-density lipoprotein nanoparticles Egg sphingomyelin (eSM), apolipoprotein A-1 mimetic peptide 22A 11.3 n/d Dtx + Cho-CpG Co-lyophilisation Colon In vitro–MC-38 cells
In vivo-mice		 [94]
NPs PBAE 137.9 ± 2.09 20.36 ± 0.01 Dtx + ATRA Solvent displacement Breast In vitro-HUVEC and MCF-7 cells [100]
micelles Cap, HA, PLA 144 n/d Dtx + Zol Dialysis Prostate In vitro–PC-3 cells
In vivo-mice		 [101]
NPs PEG 153.1 n/d Dtx + Dha Dialysis Breast In vitro–4T1 cells
In vivo-mice		 [102]
NPs H1 nanopolymer (folate–-polyethylenimine600–cyclodextrin) 117 ± 12.9 n/d Dtx + dbait N/d Prostate In vitro–CRPC, PC-3, DU145, LNCaP cells
In vivo-mice		 [96]
NPs PEG, PLA, ACUPA 135 ± 15 45 ± 5 Dtx + Gba Solvent-evaporation Prostate In vitro–PC-3, LNCaP cells [103]
NPs PLGA, PM 98.2 92.4 Dtx Dialysis Lung cancer In vitro–A549 cells
In vivo-mice		 [104]

ACUPA—((S)-2-(3-((S)-5-amino-1-carboxypentyl) ureido) pentanedioic acid; Au—gold; Cap—calcium phosphate; CHOL—cholesterol; cho-CpG-cholesterol-modified Toll-like receptor 9 (TLR9) agonist oligonucleotide; CS—chitosan; DA-deoxycholic acid; DDS—drug delivery system; DGC-N-deoxycholic acid glycol chitosan; DSPE-PEG2000-1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(poly(ethylene glycol)-2000]; EE—encapsulation efficiency; FA—folic acid; Gba—galbanic acid; GNRs-gold nanorods; GXI—gastric cancer angiogenesis marker peptide; HA—hyaluronic acid; HSPC—hydrogenated phosphatidylcholine; PBAE—poly(β-amino ester); PCL—poly(ε-caprolactone); PEG—poly(ethylene glycol); PLA—poly(lactide); PLGA—poly(lactide-co-glycolide); PLGA-ATRA—poly(lactide-co-glycolide) all-trans-retinoic acid; PM—platelet membrane; Ptx—paclitaxel; RLT—low-density lipoprotein receptor (LDLR)-binding peptide; SPC—phosphatidylcholine; STTP—chitosan and sodium tripolyphosphate; Zol—zoledronate.